

**Japan Cancer Therapeutics Market Assessment, By Applications [Lung Cancer, Blood Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Glioblastoma, Head & Neck Cancer, Malignant Meningioma, Mesothelioma, Melanoma, Others], By Therapeutics [Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other], By Top Selling Drugs [Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, Others], By End-user [Hospitals, Specialty Clinics, Cancer & Radiation Therapy Centers], By Region, By Opportunities and Forecast, FY2017-FY2031F**

Market Report | 2024-04-19 | 108 pages | Market Xcel - Markets and Data

**AVAILABLE LICENSES:**

- Single User License \$3300.00
- Multi-User/Corporate Licence \$4500.00
- Custom Research License \$7000.00

**Report description:**

Japan Cancer Therapeutics Market size was valued at USD 10.2 billion in FY2023, which is expected to reach USD 19.9 billion in FY2031, with a CAGR of 8.7% for the forecast period between FY2024 and FY2031. Several factors propel the Japan cancer therapeutics market forward, encompassing the growing incidence of cancer, heightened demand for cancer treatments, substantial government backing, a robust presence of pharmaceutical corporations, Japan's aging demographics, the increasing occurrence of lifestyle-related cancers, and the rising utilization of telemedicine and remote patient monitoring. These factors collectively contribute to the dynamic growth of Japan's cancer therapeutics market, offering cancer patients enhanced access to

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

care while reducing the need for hospital or clinic visits.

The Japan cancer therapeutics market is leading the way in healthcare advancements, shaped by a convergence of significant factors that define its dynamic terrain. Among these factors, the escalating incidence of cancer within the nation emphasizes the pressing need for innovative therapeutic remedies. As Japan grapples with an aging population, cancer rates have surged, necessitating comprehensive approaches encompassing diagnosis, treatment, and patient care. Japan cancer therapeutics market is further driven by the increasing demand for effective cancer treatments. Patients and healthcare providers actively seek state-of-the-art therapies to combat the diverse spectrum of cancers affecting the populace.

The pivotal role played by the Japanese government is integral to the growth of Japan cancer therapeutics market. Through its policies, funding, and initiatives, it provides substantial support to advance cancer research, early detection methods, and treatment modalities. The presence of influential pharmaceutical companies, both domestic and international, significantly contribute to the market's vitality. These companies are at the forefront of pioneering research and development endeavors, bringing innovative therapies and treatment options to the forefront. Furthermore, the rising incidence of lifestyle-related cancers accentuates the need for personalized interventions and treatments. The adoption of telemedicine and remote patient monitoring is gaining momentum, revolutionizing cancer care delivery by offering accessible and convenient options for patients. In this dynamic landscape, the Japan cancer therapeutics market embodies a commitment to combating cancer and improving the well-being of those impacted by this formidable disease.

#### Increase in the Lifespan

Extended lifespans signify advancements in healthcare, lifestyle improvements, and societal conditions, and they entail a heightened susceptibility to cancer. Individuals accumulate greater exposure to risk factors like environmental toxins and genetic mutations with time. Consequently, the prevalence of cancer rises as people enjoy longer lives, contributing to the increased mortality rates. This increase in cancer-related deaths across the entire population can be ascribed to the burgeoning life expectancy, a prominent trend in Japan. This trend arises from the nation's rapidly aging demographic, characterized by a growing proportion of elderly citizens. In 2022, Japan achieved an impressive life expectancy of 84.91 years, representing a noteworthy 0.14% increment compared to the previous year. This substantial increase in life expectancy has led to a significant rise in the number of cancer cases, driving greater demand within Japan cancer therapeutics market.

#### Novel Cancer Therapies

Japanese scientists are leading in pioneering cancer therapy breakthroughs. Their inventive strategies aspire to transform the landscape of Japan cancer therapeutics market. These endeavors encompass innovative methods designed to pinpoint cancer cells with greater precision while mitigating the damage to surrounding healthy tissue. This can potentially diminish the typical side effects linked to existing therapies. By harnessing state-of-the-art technologies and scientific knowledge, Japan's research community is dedicating immense effort to enhance the efficacy and availability of cancer treatments. In doing so, they provide optimism for improved patient outcomes and a better global response to the battle against cancer. A novel approach, spearheaded by Katsunori Tanaka at Japan's RIKEN Cluster for Pioneering Research (CPR) and Hiromitsu Haba at the RIKEN Nishina Centre for Accelerator-Based Science (RNC), has been devised.

The techniques are effective for treating various types of cancer with reduced adverse effects compared to current methodologies. A proof-of-concept investigation published on June 27, 2023, in the Journal of Chemical Science demonstrated that following a single injection of a compound engineered to emit minimal amounts of alpha radiation within cancer cells, tumors in mice exhibited nearly a threefold reduction in growth, leading to 100% survival. Importantly, this approach selectively targets cancer cells while preserving healthy tissue.

#### Government Initiatives

Japan's government has taken a leading role in promoting significant initiatives in the field of cancer research, which ultimately acts as a big support to Japan cancer therapeutics market. Recognizing the urgency of addressing cancer-related challenges among its populace, Japan has allocated substantial resources and exerted significant efforts to drive progress in this domain. These initiatives encompass a broad range of activities, including funding innovative research projects, facilitating collaboration between academic and medical institutions, and implementing national cancer control programs. The government's proactive approach to cancer research demonstrates its commitment to improving healthcare outcomes and improving its citizens' overall health and well-being. For example, in December 2022, the IAEA initiated the Rays of Hope Partnership in collaboration with 11

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Japanese universities and institutions. This partnership aims to bolster cancer care across Asia and the Pacific, particularly in regions lacking access to radiotherapy or facing disparities in healthcare. Rays of Hope emphasizes a selected range of high-impact, cost-efficient, and sustainable interventions that align with each nation's specific healthcare needs and commitments.

#### Increasing Interest in Immunotherapy

Immunotherapies have witnessed a prominent increase in demand as a favored cancer treatment method, which is beneficial for Japan cancer therapeutics market. These therapies represent an innovative approach to combat cancer by harnessing the body's immune system. Several factors contribute to their rising appeal. To begin with, immunotherapies have exhibited impressive efficacy in specific cancer types, frequently yielding enduring and sustainable outcomes. Furthermore, the Japanese healthcare system's dedication to innovation, thorough clinical testing, and approval procedures have streamlined the integration of state-of-the-art immunotherapies into the healthcare market, enhancing patient access.

For example, in January 2022, the American multinational pharmaceutical company Bristol-Myers Squibb K.K. announced the approval of Abecma (idecabtagene vicleucel) by the Japan's Ministry of Health, Labor and Welfare. Abecma is a chimeric antigen receptor (CAR) T cell immunotherapy directed towards B-cell maturation antigen (BCMA). The approval allows its use in treating adult patients grappling with relapsed or refractory (R/R) multiple myeloma.

#### Rising Cases of Lung Cancer

The alarming rise in lung cancer cases is leading to substantial growth in Japan cancer therapeutics market. Lung cancer is a prominent health concern in Japan, with a notable emphasis on METex14 metastatic non-small cell lung cancer (NSCLC). This variant of lung cancer, characterized by MET exon 14 skipping mutations, is overly aggressive and poses a significant threat to patients. Every year, around 3,000 individuals in Japan receive a diagnosis of METex14 metastatic NSCLC, underscoring the substantial impact of this disease on the population. Lung cancer is a prominent health concern in Japan, with a notable emphasis on METex14 metastatic non-small cell lung cancer (NSCLC).

For example, in June 2020, Novartis Pharma K.K. disclosed that Japan's Ministry of Health, Labor and Welfare (MHLW) approved Tabrecta. Tabrecta is an oral MET inhibitor designed to treat advanced and recurrent unresectable non-small cell lung cancer (NSCLC) with a specific genetic mutation known as MET exon 14 skipping (METex14). This approval extends to first-line and previously treated patients, irrespective of their prior treatment history.

#### Impact of COVID-19

The pandemic disrupted cancer care services in Japan, causing delays in diagnosis and treatment. Several factors contributed to this disruption, including strain on Japan's healthcare system, resulting in delayed cancer care services. Many individuals, including cancer patients, also hesitated to seek medical attention due to concerns about contracting COVID-19 in healthcare facilities. Consequently, the number of cancer diagnoses and treatments decreased during the initial stages of the pandemic in Japan. However, there has been significant improvement recently, with cancer care services returning to normalcy. The COVID-19 pandemic is anticipated to positively impact the Japanese cancer therapeutics market in the long term. This is because the pandemic has underscored the significance of early cancer detection and treatment. Consequently, more individuals are expected to engage in cancer screening initiatives and promptly seek medical assistance if they exhibit any cancer-related symptoms.

#### Key Players Landscape and Outlook

In Japan's cancer therapeutics market's dynamic landscape, collaboration is a fundamental driver of innovation. With an aging population and increasing cancer challenges, partnerships between pharmaceutical firms, research entities, and healthcare providers have gained paramount importance. These collaborative endeavors facilitate the creation of state-of-the-art therapies, innovative treatment strategies, and progress in cancer care. Within this competitive environment, cooperation plays a pivotal role in the relentless pursuit of enhanced treatments and better results for cancer patients in Japan.

For instance, in February 2022, Ono Pharmaceutical Co., Ltd., one of Japan's leading pharmaceutical firms, and Bristol-Myers Squibb K.K., an American multinational pharmaceutical company, jointly announced the signing of an outsourcing agreement with Prime Research Institute for Medical RWD, Inc. (based in Kyoto, Japan and referred to as "PRiME-R"). This collaboration aims to facilitate an industry-sponsored, large-scale, multi-institutional clinical research initiative focused on patients with gastric cancer receiving treatment with Opdivo (nivolumab) in combination with chemotherapy. The study will leverage PRiME-R's data input support system, "CyberOncology," designed to standardize, structure, manage, and integrate real-world data derived from routine

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

cancer clinical practices.

## **Table of Contents:**

1. □ Research Methodology
2. □ Project Scope & Definitions
3. □ Impact of Covid-19 on Japan Cancer Therapeutics Market
4. □ Executive Summary
5. □ Japan Cancer Therapeutics Market Outlook, FY2017-FY2031F
  - 5.1. □ Market Size & Forecast
    - 5.1.1. □ By Value
    - 5.1.2. □ By Volume
  - 5.2. □ By Application
    - 5.2.1. □ Lung Cancer
    - 5.2.2. □ Blood Cancer
    - 5.2.3. □ Colorectal Cancer
    - 5.2.4. □ Prostate Cancer
    - 5.2.5. □ Breast Cancer
    - 5.2.6. □ Cervical Cancer
    - 5.2.7. □ Glioblastoma
    - 5.2.8. □ Head & Neck Cancer
    - 5.2.9. □ Malignant Meningioma
    - 5.2.10. □ Mesothelioma
    - 5.2.11. □ Melanoma
    - 5.2.12. □ Others
  - 5.3. □ By Therapeutics
    - 5.3.1. □ Chemotherapy
    - 5.3.2. □ Targeted Therapy
    - 5.3.3. □ Immunotherapy
    - 5.3.4. □ Hormonal Therapy
    - 5.3.5. □ Other
  - 5.4. □ By Top Selling Drugs
    - 5.4.1. □ Revlimid
    - 5.4.2. □ Avastin
    - 5.4.3. □ Herceptin
    - 5.4.4. □ Rituxan
    - 5.4.5. □ Opdivo
    - 5.4.6. □ Gleevec
    - 5.4.7. □ Velcade
    - 5.4.8. □ Imbruvica
    - 5.4.9. □ Ibrance
    - 5.4.10. □ Zytiga
    - 5.4.11. □ Alimta
    - 5.4.12. □ Xtandi
    - 5.4.13. □ Tarceva
    - 5.4.14. □ Perjeta
    - 5.4.15. □ Temodar

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.4.16. Others
- 2.1. By End-user
  - 2.1.1. Hospitals
  - 2.1.2. Specialty Clinics
  - 2.1.3. Cancer & Radiation Therapy
- 2.2. By Region
  - 2.2.1. North [Hokkaido and Tohoku]
  - 2.2.2. Central [Kanto and Chubu]
  - 2.2.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
- 2.3. By Company Market Share (%), FY2023
- 6. Market Mapping, FY2023
  - 6.1. By Application
  - 6.2. By Therapeutics
  - 6.3. By Top Selling Drugs
  - 6.4. By End-user
  - 6.5. By Region
- 7. Macro Environment and Industry Structure
  - 7.1. Supply Demand Analysis
  - 7.2. Import Export Analysis
  - 7.3. Value Chain Analysis
  - 7.4. PESTEL Analysis
    - 7.4.1. Political Factors
    - 7.4.2. Economic System
    - 7.4.3. Social Implications
    - 7.4.4. Technological Advancements
    - 7.4.5. Environmental Impacts
    - 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  - 7.5. Porter's Five Forces Analysis
    - 7.5.1. Supplier Power
    - 7.5.2. Buyer Power
    - 7.5.3. Substitution Threat
    - 7.5.4. Threat from New Entrant
    - 7.5.5. Competitive Rivalry
- 8. Market Dynamics
  - 8.1. Growth Drivers
  - 8.2. Growth Inhibitors (Challenges and Restraints)
- 9. Regulatory Framework and Innovation
  - 9.1. Clinical Trials
  - 9.2. Patent Landscape
  - 9.3. Regulatory Approvals
  - 9.4. Innovations/Emerging Technologies
- 10. Key Players Landscape
  - 10.1. Competition Matrix of Top Five Market Leaders
  - 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
  - 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  - 10.4. SWOT Analysis (For Five Market Players)
  - 10.5. Patent Analysis (If Applicable)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11. Pricing Analysis
- 12. Case Studies
- 13. Key Players Outlook
  - 13.1. Daiichi Sankyo Company, Ltd.
    - 13.1.1. Company Details
    - 13.1.2. Key Management Personnel
    - 13.1.3. Products & Services
    - 13.1.4. Financials (As reported)
    - 13.1.5. Key Market Focus & Geographical Presence
    - 13.1.6. Recent Developments
  - 13.2. Takeda Pharmaceutical Company Ltd.
  - 13.3. Chugai Pharmaceutical Co., Ltd.
  - 13.4. Astellas Pharma Inc.
  - 13.5. Otsuka Pharmaceutical Co., Ltd.
  - 13.6. Eisai Co., Ltd.
  - 13.7. Shionogi & Co., Ltd.
  - 13.8. Kyowa Kirin Co., Ltd.
  - 13.9. Ono Pharmaceutical Co., Ltd.
  - 13.10. Sumitomo Pharma Co., Ltd.
  - 13.11. Novartis Pharma K.K.
  - 13.12. Bristol-Myers Squibb Company Ltd.
  - 13.13. Janssen Pharmaceutical K.K.
  - 13.14. AstraZeneca Pharma Japan Ltd.
  - 13.15. Pfizer Japan Inc.

\*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

- 14. Strategic Recommendations
- 15. About Us & Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Japan Cancer Therapeutics Market Assessment, By Applications [Lung Cancer, Blood Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Glioblastoma, Head & Neck Cancer, Malignant Meningioma, Mesothelioma, Melanoma, Others], By Therapeutics [Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other], By Top Selling Drugs [Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, Others], By End-user [Hospitals, Specialty Clinics, Cancer & Radiation Therapy Centers], By Region, By Opportunities and Forecast, FY2017-FY2031F**

Market Report | 2024-04-19 | 108 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3300.00
	Muti-User/Corporate Licence	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

□\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com